Login to Your Account

San Antonio Breast Cancer Symposium

Genentech's Pertuzumab Shows 6-Month PFS Gain

By Marie Powers
Staff Writer

Friday, December 9, 2011

Findings from Genentech Inc.'s randomized Phase III CLEOPATRA study of pertuzumab in HER2-positive metastatic breast cancer suggested the drug, in combination with Herceptin (trastuzumab) and docetaxel chemotherapy, provided a 38 percent improvement in progression-free survival (PFS) compared to Herceptin and docetaxel alone in previously untreated HER2-positive metastatic breast cancer (mBC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription